In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.

Member Benefit

This content is only available year-round to ESC Professional Members, Fellows of the ESC, and Young Combined Members

CMR survey in a large cohort of TI patients categorized in different transfusional regimens

Session Rapid Fire - Cardiac multimodality imaging in systemic diseases

Speaker Antonella Meloni

Event : ESC Congress 2013

  • Topic : imaging
  • Sub-topic : Cardiac Magnetic Resonance (CMR)
  • Session type : Rapid Fire Abstracts

Authors : A Meloni (Pisa,IT), S Vacquer (Cagliari,IT), ME Lai (Cagliari,IT), L Gulino (Pisa,IT), S Campisi (Siracusa,IT), D De Marchi (Pisa,IT), M Midiri (Palermo,IT), V Positano (Pisa,IT), M Lombardi (Pisa,IT), A Pepe (Pisa,IT)

A. Meloni1 , S. Vacquer2 , M.E. Lai2 , L. Gulino1 , S. Campisi3 , D. De Marchi1 , M. Midiri4 , V. Positano1 , M. Lombardi1 , A. Pepe1 , 1CMR Unit, Fondazione G.Monasterio CNR-Regione Toscana and Institute of Clinical Physiology - Pisa - Italy , 2Ospedale microcitemico Centro Talassemici Adulti - Cagliari - Italy , 3U.O.S. Talassemia - A.O. Umberto I - Siracusa - Italy , 4Istituto di Radiologia Policlinico "Paolo Giaccone" - Palermo - Italy ,

Cardiovascular Magnetic Resonance (CMR)

European Heart Journal ( 2013 ) 34 ( Abstract Supplement ), 829

Purpose: We investigated myocardial iron overload (MIO), biventricular parameters and myocardial fibrosis assessed by cardiovascular magnetic resonance (CMR) in a large cohort of thalassemia intermedia (TI) patients categorized in different transfusional regimens. This survey is particularly significant considering the debate on the opportunity to transfuse the TI patients.

Methods: We studied retrospectively 252 adult TI patients (119 females, 39±10 yrs) enrolled in the MIOT Network. MIO was assessed by a multislice multiecho T2* approach. Cine sequences were obtained to quantify biventricular function parameters. Myocardial fibrosis was evaluated by late gadolinium enhancement (LGE) acquisitions.

Results: 188 patients showed no MIO in any segment, 56 had an heterogeneous MIO (52 with a global heart T2*<20 ms), and 8 showed an homogeneous MIO.

Left ventricular (LV) and right ventricular (RV) dilatations were present in the 45% and in the 19% of cases, respectively. LV dysfunction was present in the 18.0% of the cases while RV dysfunction in the 3.63%. LV hypertrophy was found in the 8.7% of cases.

Myocardial fibrosis was found in the 22.9% of the patients and was associated with LV dysfunction (P=0.001) and hypertrophy (P=0.038).

48 patients were no transfused, 66 sporadically transfused and 138 regularly transfused. The 3 group were significantly different for the LV volume and mass indexes, the cardiac output and the myocardial fibrosis (Table).

Conclusions: Heart iron was not absent in TI and the majority of the patients showed an heterogeneous distribution. A consistent number of the TI patients had the stigmata of the high cardiac output state cardiomyopathy and myocardial fibrosis seems to be related to the high cardiac output state. The signs of the high cardiac output state were controlled in the regular transfused patients. Conversely, the regular transfusions seem to be started too late for preventing myocardial fibrosis.

LV stroke volume (ml/m2)63±1363±1257±130.015
LV mass index (g/m2)72±1468±1464±130.001
LV cardiac output (l/min)6.9±2.46.9±2.46.1±2.30.026
Fibrosis –%8.727.126.10.037

Member Benefit

This content is only available year-round to ESC Professional Members, Fellows of the ESC, and Young Combined Members

Get your access to resources

Join now
  • 1ESC Professional Members – access all ESC Congress resources 
  • 2ESC Association Members (Ivory, Silver, Gold) – access your Association’s resources
  • 3Under 40 or in training - with a Combined Membership, access all resources
Join now
logo esc

Our mission: To reduce the burden of cardiovascular disease

Who we are